Table 2.
STING agonists in combination with ICBs
| STING agonist | ICB | Cancer type | Trial NO | Phase | Status | Refs. |
|---|---|---|---|---|---|---|
| ADU-S100 | Ipilimumab | Advanced Solid Tumors or Lymphomas | NCT02675439 | 1 | Active, not recruiting | |
| Spartalizumab | Advanced Solid Tumors or Lymphomas | NCT03172936 | 1 | Completed | [140] | |
| Pembrolizumab | Metastatic or Recurrent HNSCC | NCT03937141 | 2 | Active, not recruiting | ||
| MK-1454 | Pembrolizumab | Advanced/Metastatic Solid Tumors or Lymphomas | NCT03010176 | 1 | Active, not recruiting | [141] |
| Metastatic or Unresectable, Recurrent HNSCC | NCT04220866 | 2 | Active, not recruiting | |||
| SYNB1891 | Atezolizumab | Advanced/Metastatic Solid Tumors or Lymphomas | NCT04167137 | 1 | Recruiting | |
| MK-2118 | Pembrolizumab | Advanced/Metastatic Solid Tumors or Lymphomas | NCT03249792 | 1 | Recruiting | |
| GSK3745417 | Dostarlimab | Advanced Solid Tumors | NCT03843359 | 1 | Recruiting | |
| SNX281 | Pembrolizumab | Advanced Solid Tumors and Lymphoma | NCT04609579 | 1 | Recruiting | |
| BMS-986301 | Nivolumab or Ipilimumab | Advanced Solid Tumors | NCT03956680 | 1 | Recruiting | |
| SB11285 | Atezolizumab | Advanced Solid Tumors | NCT04096638 | 1 | Recruiting |